ArticleNature2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2,861 papers.
0numbers the graph read from it
0cells of the map it votes in
2,861citing papers in PubMed
584.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols
Who cites it
2,861 citing papers in PubMed, 4,813 citations in OpenAlex.
- Metformin and Time to Sustained Recovery in Adults With COVID-19: The ACTIV-6 Randomized Clinical Trial.JAMA internal medicine · 2025Trial
- Epitope Tagging and Coimmunoprecipitation to Identify Viral Protein Interactors.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.Virulence · 2026Review
- Transcription Regulatory Sequences in Coronaviruses: Mechanistic Foundations for Antivirals and Vaccines.Journal of microbiology and biotechnology · 2026Review
- Transforming the Landscape of Drug Innovation in AI Era: AlphaFold 3 and Beyond.Exploration (Beijing, China) · 2026Article
- Article
- Circulating cholesterol fuels SARS-CoV-2 replication via ORF3a.EMBO reports · 2026Article
- Article
- Sarbecoviruses Suppress Innate Immunity by Recruiting PPM1A to Modulate STAT2 and ORF9b Phosphorylation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nsp3 Ubl1-orchestrated dephosphorylation of N protein promotes coronaviral subgenomic RNA synthesis.bioRxiv : the preprint server for biology · 2026Article
- Secreted ORF8 reprograms macrophages to enhance SARS-CoV-2 infection of lung epithelial cells.Science advances · 2026Article
- An ATP-Driven N Protein-DDX21 Molecular Switch Dynamically Controls SARS-CoV-2 RNA G-Quadruplex Heterogeneity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The accessory protein ORF3a hijacks the CLCC1 chloride channel to disrupt ER homeostasis in betacoronavirus pathogenesis.Cell discovery · 2026Article
- Native Label-Free Spectral Biochemical Fingerprinting of an Enveloped Mammalian RNA Virus Reveals Mode of Action of a Virucidal Drug.Small methods · 2026Article
- Comparative proteomics of human naso-oropharyngeal swabs from COVID19 patients for identification of potential biomarker candidates.Biochemistry and biophysics reports · 2026Article
- PhoSARte: identification of SARS-CoV-2 phosphorylation sites using contrastive learning and protein language models.Briefings in bioinformatics · 2026Article
- A P3' methionine-to-phenylalanine substitution in the NSP6-7 substrate peptide alters SARS-CoV-2 MThe Journal of biological chemistry · 2026Article
- Modeling Risk Group 4 virus infection and antiviral treatment in microfluidic lung organ-on-chips in maximum containment laboratories.bioRxiv : the preprint server for biology · 2026Article
- The diverse functions of viral microproteins.bioRxiv : the preprint server for biology · 2026Article
- Article
2,801 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Update of
Authors and funding
125 authors at 15 institutions in 3 countries.
David E Gordon *QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7954-0306
Gwendolyn M Jang *QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Mehdi Bouhaddou *QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Jiewei Xu *QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Kirsten Obernier *QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-4025-1299
Kris M White *Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0889-0506
Matthew J O'Meara *Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-3128-5331
Veronica V Rezelj *Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Jeffrey Z GuoQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Danielle L SwaneyQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6119-6084
Tia A TumminoQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9155-820X
Ruth HüttenhainQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-0896-5910
Robyn M KaakeQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Alicia L RichardsQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-4869-2945
Beril TutuncuogluQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5458-2988
Helene FoussardQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5063-113X
Jyoti BatraQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Kelsey HaasQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Maya ModakQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-0670-6683
Minkyu KimQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9317-1658
Paige HaasQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8303-457X
Benjamin J PolaccoQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1570-9234
Hannes BrabergQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-7070-2257
Jacqueline M FabiusQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Manon EckhardtQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Margaret SoucherayQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Melanie J BennettQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6293-8008
Merve CakirQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1803-5693
Michael J McGregorQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Qiongyu LiQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Bjoern MeyerViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Ferdinand RoeschViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0003-0702-7778
Thomas ValletViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0001-7775-7448
Alice Mac KainViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0002-5218-6690
Lisa MiorinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Elena MorenoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-2301-4558
Zun Zar Chi NaingQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6320-5084
Yuan ZhouQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-1393-5476
Shiming PengQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5830-243X
Ying ShiQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9263-4320
Ziyang ZhangQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0541-7211
Wenqi ShenQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8657-4931
Ilsa T KirbyQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
James E MelnykQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1915-8089
John S ChorbaQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-6397-6348
Kevin LouQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4939-4381
Shizhong A DaiQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-9679-2353
Inigo Barrio-HernandezEuropean Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-5686-0451
Danish MemonEuropean Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-1365-0710
Claudia Hernandez-ArmentaEuropean Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Cambridge, UK.
Jiankun LyuQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Christopher J P MathyQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5546-9733
Tina PericaQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3152-8425
Kala Bharath PillaQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8327-1687
Sai J GanesanQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8335-2866
Daniel J SaltzbergQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Ramachandran RakeshQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7196-5078
Xi LiuQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Sara B RosenthalCenter for Computational Biology and Bioinformatics, Department of Medicine, University of California San Diego, San Diego, CA, USA.ORCID http://orcid.org/0000-0002-6548-9658
Lorenzo CalvielloQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5600-0988
Srivats VenkataramananQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2507-401X
Jose Liboy-LugoQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9997-2285
Yizhu LinQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Xi-Ping HuangDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
YongFeng LiuDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Stephanie A WankowiczQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-4225-7459
Markus BohnQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Maliheh SafariQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Fatima S UgurQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Cassandra KohViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0003-2466-6731
Nastaran Sadat SavarViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0003-2509-2127
Quang Dinh TranViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0002-9263-0733
Djoshkun ShengjulerViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0002-6286-9727
Sabrina J FletcherViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.
Michael C O'NealZoic Labs, Culver City, CA, USA.ORCID http://orcid.org/0000-0002-3905-2671
Yiming CaiZoic Labs, Culver City, CA, USA.
Jason C J ChangZoic Labs, Culver City, CA, USA.
David J BroadhurstZoic Labs, Culver City, CA, USA.ORCID http://orcid.org/0000-0001-9816-115X
Saker KlippstenZoic Labs, Culver City, CA, USA.ORCID http://orcid.org/0000-0002-9749-6756
Phillip P SharpDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-4416-2303
Nicole A WenzellQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8209-2249
Duygu Kuzuoglu-OzturkQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Hao-Yuan WangQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8490-8793
Raphael TrenkerQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1748-0517
Janet M YoungDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-8220-8427
Devin A CaveroQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Joseph HiattQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Theodore L RothQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-3970-9573
Ujjwal RathoreQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Advait SubramanianQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Julia NoackQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9113-8181
Mathieu HubertVirus and Immunity Unit, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0002-2190-0177
Robert M StroudQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Alan D FrankelQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Oren S RosenbergQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5736-4388
Kliment A VerbaQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
David A AgardQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3512-695X
Melanie OttQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Michael EmermanDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-4181-6335
Natalia JuraQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5129-641X
Mark von ZastrowQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1375-6926
Eric VerdinQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3703-3183
Alan AshworthQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Olivier SchwartzVirus and Immunity Unit, Institut Pasteur, Paris, France.
Christophe d'EnfertDirection Scientifique, Institut Pasteur, Paris, France.ORCID http://orcid.org/0000-0002-6235-3886
Shaeri MukherjeeQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Matt JacobsonQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6262-655X
Harmit S MalikDivision of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-6005-0016
Danica G FujimoriQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Trey IdekerQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-1708-8454
Charles S CraikQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-7704-9185
Stephen N FloorQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
James S FraserQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5080-2859
John D GrossQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-1377-4705
Andrej SaliQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Bryan L RothDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-0561-6520
Davide RuggeroQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Jack TauntonQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Tanja KortemmeQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-8494-680X
Pedro BeltraoQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-2724-7703
Marco VignuzziViral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, Paris, France. marco.vignuzzi@pasteur.fr.ORCID http://orcid.org/0000-0002-4400-771X
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.ORCID http://orcid.org/0000-0002-6551-1827
Kevan M ShokatQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.ORCID http://orcid.org/0000-0001-8590-7741
Brian K ShoichetQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. shoichet@cgl.ucsf.edu.
Nevan J KroganQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. nevan.krogan@ucsf.edu.ORCID http://orcid.org/0000-0003-4902-337X
University of California, San Francisco · USGladstone Institutes · USCentre National de la Recherche Scientifique · FRHoward Hughes Medical Institute · USEuropean Bioinformatics Institute · GBFred Hutch Cancer Center · USIcahn School of Medicine at Mount Sinai · USInstitut Pasteur · FRQB3 · USUniversity of North Carolina at Chapel Hill · USBuck Institute for Research on Aging · USTisch Hospital · USUniversity of California San Diego · USUniversity of Michigan · USUniversity of San Diego · US
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MThe role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PORTNOY, DANIEL A · 2004 to 2025
$45.5MVirology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2MSARS-CoV adaptations through a Systems Biology Lens (SYBIL)U19AI135972 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Adolfo Garcia-Sastre · 2018 to 2026
$27.2MRESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2018 to 2026
$21.4MX-ray Screening and Rapid Structure DeterminationP50AI150476 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EMERMAN, MICHAEL · 2019 to 2021
$14.4MMolecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4MSTRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008284 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORTEMME, TANJA · 1988 to 2022
$10.1MDevelopment and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5MRESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8MSTRUCTURE/FUNCTION OF PROTEINS AT MOLECULAR LEVELR01GM024485 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STROUD, ROBERT M · 1985 to 2024
$7.5MHoward Hughes Medical InstituteNCI NIH HHS F30 CA239476NCI NIH HHS F32 CA236347NCI NIH HHS F32 CA239333NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA221969NCI NIH HHS R01 CA244550NCI NIH HHS T32 CA108462NHGRI NIH HHS R01 HG009979NHLBI NIH HHS K08 HL124068NIAID NIH HHS HHSN272201400008CNIAID NIH HHS P01 AI063302NIAID NIH HHS P01 AI120943NIAID NIH HHS P30 AI027763NIAID NIH HHS P50 AI150476NIAID NIH HHS R01 AI118974NIAID NIH HHS R01 AI120694NIAID NIH HHS R01 AI122747NIAID NIH HHS R01 AI143292NIAID NIH HHS T32 AI060537NIAID NIH HHS U19 AI135972NIAID NIH HHS U19 AI135990NIGMS NIH HHS F32 GM133144NIGMS NIH HHS R01 GM024485NIGMS NIH HHS R01 GM117189NIGMS NIH HHS R01 GM140440NIGMS NIH HHS R35 GM118099NIGMS NIH HHS R35 GM122481NIGMS NIH HHS T32 GM008284NIGMS NIH HHS T32 GM064337NIGMS NIH HHS T32 GM067547NIH HHS 1F32CA236347-01NIH HHS 1R01CA244550
Abstract
A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption
Indexed as
Drug RepositioningMolecular Targeted TherapyProtein Interaction MapsAnimalsAntiviral AgentsBetacoronavirusChlorocebus aethiopsCloning, MolecularCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug Evaluation, PreclinicalHEK293 CellsHost-Pathogen InteractionsHumansImmunity, InnateAntiviral AgentsReceptors, sigmaSKP Cullin F-Box Protein LigasesViral Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04510194ClinicalTrials.gov
NCT05862883ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.